Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (Nasdaq: CMPS) launched a proposed public offering of $150.0 million of American Depositary Shares (ADSs) and, for certain institutional investors, pre-funded warrants. The company also expects to grant underwriters a 30-day option to buy up to an additional $22.5 million of ADSs.
The offering is subject to market conditions and will be made from a shelf registration effective May 7, 2025; a preliminary prospectus supplement will be filed with the SEC.
Compass Pathways (Nasdaq: CMPS) reported that the Phase 3 COMP006 trial met its primary endpoint: two 25 mg doses of COMP360 produced a highly statistically significant -3.8 point MADRS improvement versus 1 mg at Week 6 (p<0.001).
Across COMP005 and COMP006, rapid onset from Day 1, durable responses in some participants through Week 26, a generally well-tolerated safety profile, and a planned NDA submission in Q4 were announced.
Compass Pathways (Nasdaq: CMPS) said it will release new clinical data from two ongoing Phase 3 trials of COMP360, its proprietary synthetic psilocybin, on February 17, 2026 at 6:30 am ET.
The company will disclose Part A and Part B results from COMP005 and Part A from COMP006, followed by a live audio webcast with management at 8:00 am ET; a replay will be available for 30 days.
Compass Pathways (Nasdaq: CMPS) announced the U.S. FDA has accepted its IND for COMP360 in PTSD, enabling initiation of a Phase 2b/3 (COMP202) trial with a 12-week blinded Part A and 40-week open-label Part B; the primary endpoint is change in CAPS-5 at Week 8. Compass said prior Phase 2 open-label PTSD data showed rapid, durable symptom improvement (published September 2025). The company also reviewed commercial readiness for COMP360 in TRD and disclosed planned data timing: second half of Q1 2026 for combined COMP006/COMP005 readouts and COMP006 Part B 26-week data expected early Q3 2026. Financially, Compass amended a Hercules loan to up to $150M with $50M drawn, extended interest-only through at least January 5, 2029, and extended maturity to January 5, 2031.
Compass Pathways (Nasdaq: CMPS) announced a strategic collaboration with Radial Health to explore integration of investigational COMP360 synthetic psilocybin treatment into Radial’s growing U.S. interventional psychiatry clinic network.
The agreement is Compass’s seventh strategic collaboration and will inform scalable delivery models for COMP360 if FDA approved. Radial operates across five states, offers virtual assessments nationwide, and was co-founded by executives with prior consumer-healthcare experience. The collaboration aims to identify operational and patient‑experience learnings to enable seamless integration at launch.
Compass Pathways (Nasdaq: CMPS) will host a webinar on January 7, 2026, 10:00–11:30 am ET to discuss commercial preparations for treatment-resistant depression (TRD) and planned late-stage clinical trials for post-traumatic stress disorder (PTSD).
Management and collaboration partners will cover commercial readiness, provider economics for multi-hour treatments, patient care pathways, and the emerging profile of COMP360 in TRD. The company will also outline the planned late-stage program for COMP360 in PTSD and include KOL and industry perspectives.
Speakers include Dr Gary Small, Dr Geoff Grammer, Myriam Barthes, and Dimitri Cavathas. A live audio webcast is available at https://lifescievents.com/event/q0v8tp3/, with a replay accessible for 30 days after the event.
Compass Pathways (Nasdaq: CMPS) management will participate in two December investor conferences: a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL on December 2, 2025 at 10:00am ET, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York, NY on December 3, 2025 at 1:30pm ET.
A live audio webcast of both events will be available from the company’s Investors “Events” page, with replays accessible for 30 days after each event.
Compass Pathways (Nasdaq: CMPS) confirmed management will participate in the Stifel 2025 Healthcare Conference in New York on Tuesday, November 11, 2025 at 10:40 am ET. A live audio webcast will be available from the Investors > Events page on the company website, and a replay will be accessible for 30 days following the event.
Compass Pathways (Nasdaq: CMPS) reported Q3 2025 results and said it is accelerating commercialization plans for COMP360 in treatment‑resistant depression by 9–12 months after completing enrollment in the second Phase 3 trial (COMP006, n=585) and a positive Type B FDA meeting in Sept 2025 discussing NDA strategy and potential rolling submission.
Key near‑term data milestones: 9‑week COMP006 (Part A) and 26‑week COMP005 (Part B) in Q1 2026, and 26‑week COMP006 (Part B) in early Q3 2026. Cash was $185.9M at Sept 30, 2025, and management expects cash to fund operations into 2027. Q3 net loss was $137.7M driven by a $101.3M non‑cash warrant fair‑value adjustment.
NeuroKaire and Compass Pathways (CMPS) announced an R&D collaboration on Oct 30, 2025 to apply NeuroKaire's AI-powered neural image analysis to study how psychedelic compounds affect neuron structure and connectivity.
The study will use stem cell–derived neurons from people with treatment-resistant depression (TRD) and major depressive disorder (MDD), leveraging a proprietary neuroplasticity marker to compare cellular effects across compounds and link findings to clinical phenotypes.
The collaboration aims to narrow the gap between preclinical models and patient outcomes and to inform precision approaches to psychedelic drug development.